Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461134 | 1.00 | EGFR (0.54) | EGFRALDH1A1LMNAHPGDENPP1 | |
| Hydrochloric Acid SCHEMBL28824441 | 0.98 | EGFR (0.52) | EGFRALDH1A1LMNAHPGDENPP1 | |
| SCHEMBL29923692 | 0.86 | MAPT (0.56) | EGFRALDH1A1LMNAHPGDENPP1 | |
| SCHEMBL591893 | 0.86 | MAPT (0.56) | EGFRALDH1A1LMNAHPGDENPP1 | |
| Hydrochloric Acid SCHEMBL28102779 | 0.84 | MAPT (0.55) | EGFRALDH1A1LMNAHPGDENPP1 | |
| Ethoxycarbonyl Group SCHEMBL28094497 | 0.84 | ENPP1 (0.47) | EGFRALDH1A1LMNAHPGDENPP1 | |
| SCHEMBL29235176 | 0.84 | ENPP1 (0.47) | EGFRALDH1A1LMNAHPGDENPP1 | |
| SCHEMBL30640012 | 0.83 | ENPP1 (0.55) | ALDH1A1LMNAHPGDENPP1KDM4E | |
| SCHEMBL8147583 | 0.83 | ENPP1 (0.55) | ALDH1A1LMNAHPGDENPP1KDM4E | |
| SCHEMBL4512570 | 0.82 | KDR (0.57) | EGFRENPP1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852129-A | Preparation method and application of triazole feed additive with anti-inflammatory activity designed based on deep learning technology | 河南湾流生物科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | KAGOSHIMA UNIVERSITY (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4010330-B1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | HIRUNDO BIOSCIENCES (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-5648353-A | INFLAMMATORY EDEMA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| US-5624926-A | Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-04-29 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| US-5605900-A | USEFUL FOR TREATMENT OF INFLAMMATORY EDEMA, ISCHEMIA AND REPERFUSION DISORDERS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| EP-0638567-A1 | ADENOSINE INCORPORATION INHIBITOR | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | EGFR 463/4885ALDH1A1 3476/4885LMNA 3407/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | EGFR 3299/4885ALDH1A1 2453/4885LMNA 3010/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | EGFR 457/4885ALDH1A1 3834/4885LMNA 3365/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | EGFR 4503/4885ALDH1A1 754/4885LMNA 3740/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | EGFR 1194/4885ALDH1A1 946/4885LMNA 1604/4885 |
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, AGTR2 | EGFR 459/4885ALDH1A1 2172/4885LMNA 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.